Evidence map›Paper›PMID 34863146›Full record

ArticleBMC pulmonary medicine2021

Validation of the risk stratification score in idiopathic pulmonary fibrosis: study protocol of a prospective, multi-centre, observational, 3-year clinical trial.

Gian Marco Manzetti, Karishma Hosein, Matthew J Cecchini, Keith Kwan, Mohamed Abdelrazek, Maurizio Zompatori, Paola Rogliani, Marco Mura

Registry-linked trialOpen access · goldAbstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC pulmonary medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02632123 (Validation of the Risk Stratification Score in Idiopathic Pulmonary Fibrosis), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02632123 completednot on this map

Validation of the Risk Stratification Score in Idiopathic Pulmonary Fibrosis

TypeobservationalSponsorLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sRan2015 to 2024Enrolled260ConditionsIdiopathic Pulmonary Fibrosis
3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Radiographic Progression and Survival of the Different HRCT Patterns of Idiopathic Pulmonary Fibrosis.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Gian Marco ManzettiMalattie Apparato Respiratorio, Policlinico Tor Vergata, University of Rome "Tor Vergata", Rome, Italy.
Karishma HoseinDivision of Respirology, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada.
Matthew J CecchiniDepartment of Pathology and Laboratory Medicine, Western University, London, ON, Canada.
Keith KwanDepartment of Pathology and Laboratory Medicine, Western University, London, ON, Canada.
Mohamed AbdelrazekDepartment of Medical Imaging, Western University, London, ON, Canada.
Maurizio ZompatoriRadiologia, MultiMedica Group, I.R.C.C.S. San Giuseppe Hospital, Milan, Italy.
Paola RoglianiMalattie Apparato Respiratorio, Policlinico Tor Vergata, University of Rome "Tor Vergata", Rome, Italy.
Marco MuraDivision of Respirology, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada. marco.mura@lhsc.on.ca.
Western University · CAUniversity of Rome Tor Vergata · ITMultiMedica · IT

Funding

CHEST Foundation Pulmonary Fibrosis Research Grant
6 · The paper itself

Abstract

backgroundIdiopathic pulmonary fibrosis (IPF) is characterized by a poor prognosis, with a progressive decline in lung function and considerable variability in the disease's natural history. Besides lung transplantation (LTx), the only available treatments are anti-fibrosing drugs, which have shown to slow down the disease course. Therefore, predicting the prognosis is of pivotal importance to avoid treatment delays, which may be fatal for patients with a high risk of progression. Previous studies showed that a multi-dimensional approach is practical and effective in the development of a reliable prognostic score for IPF. In the RIsk Stratification scorE (RISE), physiological parameters, an objective measure of patient-reported dyspnea and exercise capacity are combined to capture different domains of the complex pathophysiology of IPF.

methodsThis is an observational, multi-centre, prospective cohort study, designed to reflect common clinical practice in IPF. A development cohort and a validation cohort will be included. Patients newly diagnosed with IPF based on the ATS/ERS criteria and multi-disciplinary discussion will be included in the study. A panel of chest radiologists and lung pathologists will further assess eligibility. At the first visit (time of diagnosis), and every 4-months, MRC dyspnea score, pulmonary function tests (FEV DISCUSSION: The objective of this study is to validate RISE as a simple, straightforward, inexpensive and reproducible tool to guide clinical decision making in IPF, and potentially as an endpoint for future clinical trials.

trial registrationU.S National Library of Medicine Clinicaltrials.gov, trial n. NCT02632123 "Validation of the risk stratification score in idiopathic pulmonary fibrosis". Date of registration: December 16th, 2015.

Indexed as

Clinical Decision-MakingIdiopathic Pulmonary FibrosisRisk AssessmentCanadaHumansLondonMulticenter Studies as TopicObservational Studies as TopicProgram DevelopmentProspective StudiesReproducibility of ResultsRomeIdiopathic pulmonary fibrosisLung transplantationMortalityPrognosisSurvival

Identifiers

PMID34863146
PMCPMC8645123
OpenAlexW4200022884

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.